The Alzheimer’s Drug Discovery Foundation (ADDF) has made a significant $7 million investment in C2N Diagnostics, marking the largest contribution from its Diagnostics Accelerator (DxA) program to date.

This investment underscores the DxA’s focus on advancing innovative biomarkers, including blood tests, which are expected to transform Alzheimer’s diagnostics.

The development of scalable and accessible blood-based biomarkers is seen as a crucial step toward enabling precision medicine and combination therapies for Alzheimer’s, similar to those used in cancer treatment.

Blood tests have emerged as an important tool in detecting Alzheimer’s disease, with PTau217 being recognized as a leading blood-based biomarker for diagnostic purposes.

C2N’s PrecivityAD2® test has demonstrated high sensitivity and accuracy, positioning it as a less invasive alternative to traditional diagnostic methods like PET scans and spinal taps.

This funding aims to improve the accessibility of this crucial diagnostic tool, in line with DxA’s mission to bring advanced diagnostics to a broader population of Alzheimer’s patients.

C2N Diagnostics has a strong track record of innovation, with its PrecivityAD® blood test being one of the first on the market, supported by earlier ADDF funding.

The new investment will help C2N develop a global blood biomarker detection platform, similar to widely recognized diagnostics like Roche’s Elecsys and Fujirebio’s Lumipulse.

This platform aims to expand global access to high-performance Alzheimer’s testing, reinforcing the long-standing collaboration between ADDF and C2N.

C2N’s leadership acknowledges the importance of this funding, aiming to develop a comprehensive clinical mass spectrometry solution that will support decentralized and regulatory-compliant Alzheimer’s testing on a global scale.

This approach is designed to address the increasing global demand for early and accurate disease detection.

Blood-based biomarkers are part of the DxA’s broader portfolio, which also includes digital and ocular diagnostic tools. To date, the DxA has invested over $70 million in more than 60 projects. Alongside blood tests, the future of Alzheimer’s diagnostics is expected to incorporate digital and ocular tools that can be used for early diagnosis, screening, and preventive efforts.

The accessibility and scalability of biomarkers play a key role in transforming the diagnostic landscape, and advancements in Alzheimer’s blood tests are expected to accelerate drug development and clinical trials. By offering faster, cost-effective methods for patient enrollment and drug monitoring, these innovations will support the future of combination therapies and precision medicine in Alzheimer’s treatment.

 

 

Source: alzdiscovery.org

Report Abuse